Affimed Therapeutics and Biopharma Unit of Syngenta Enter Into Agreement to Co-develop Tandabs
Heidelberg. Affimed Therapeutics AG, a Heidelberg, Germany-based drug development company, has signed a partnership agreement with the biopharmaceutical unit of Syngenta AG of Basel, Switzerland to co-develop one of Affimed's proprietary Tandab antibodies.
Tandabs recruit the body's immune system and will therefore provide a powerful tool in fighting cancers and other disease. These molecules have been engineered so that they have four binding sites (tetravalent), two of those binding sites are for antigens on the cancer or diseased cell while the other two binding sites are specific for the immune systems killer cells. Tetravalency facilitates a very tight binding between the tumour and killer cells enabling extremely efficient destruction of the tumour cells.
Both companies believe the technology holds tremendous potential for creating more effective next-generation treatments. The parties will utilize Affimed's technology platform to identify and develop Tandabs for cancer and other indications. The activities are supported in part by a EUR 1 million BioChance Plus grant recently awarded to Affimed by the German government.
"We are excited to combine Affimed's Tandab platform with Syngenta's process development, pre-clinical and clinical expertise," said Prof. Melvyn Little, Scientific Founder and CSO of Affimed.
George Rehm, Board Member of Affimed and Partner at First Ventury, Affimed's lead investor commented: "This co-development agreement will allow us to take molecules into clinical development and share in the substantial incremental value created by demonstrating efficacy in human clinical trials prior to out-licensing."
"We were impressed by the strength of the team at Affimed, as well as their deep understanding of the antibody fragment technology, strong intellectual property position and close relationship with the German National Cancer Research Center," said Richard Jones, MD, Medical Director for Syngenta Biopharma. "This combination is typical of the kind of partner we're seeking and will allow the flexibility to move quickly and decisively to leverage the partnership."
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
